US Supreme Court Asked to Reconsider Gene Patents
By Ruth Saunders,
BioNews
| 10. 01. 2012
The American Civil Liberties Union (ACLU) has asked the US Supreme Court to reconsider its decision to uphold the patent held by Myriad Genetics on two human genes associated with hereditary breast and ovarian cancers.
The lawsuit was filed by ACLU and the Public Patent Foundation on behalf of medical associations including the Association for Molecular Pathology, scientists, patients and women's health groups. It is the latest part of an ongoing battle over the validity of the patents held by Myriad Genetics. The lawsuit claims the patents are illegal and will both hamper scientific research and limit accessibility to medical care.
The ruling over the gene patents has been going back and forth since March 2010, when a district court declared the patents invalid, but was later overturned by the Court of Appeal for the Federal Circuit (CAFC). The decision was passed on to the Supreme Court, which asked the CAFC to reassess their judgement taking into consideration the Supreme Court's recent ruling against a similar patent.
The genes in question, BRCA1 and BRCA2, can be used to detect the...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
